These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8646287)

  • 21. Effect of Blood Donor Characteristics on Transfusion Outcomes: A Systematic Review and Meta-Analysis.
    Chassé M; McIntyre L; English SW; Tinmouth A; Knoll G; Wolfe D; Wilson K; Shehata N; Forster A; van Walraven C; Fergusson DA
    Transfus Med Rev; 2016 Apr; 30(2):69-80. PubMed ID: 26920039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of neocyte transfusion in the management of thalassaemia.
    Spanos T; Ladis V; Palamidou F; Papassotiriou I; Banagi A; Premetis E; Kattamis C
    Vox Sang; 1996; 70(4):217-23. PubMed ID: 9123927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Red cell immunization in beta thalassaemia major.
    Bhatti FA; Salamat N; Nadeem A; Shabbir N
    J Coll Physicians Surg Pak; 2004 Nov; 14(11):657-60. PubMed ID: 15530273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous beta-thalassemia.
    Collins AF; Gonçalves-Dias C; Haddad S; Talbot R; Herst R; Tyler BJ; Zuber E; Blanchette VS; Olivieri NF
    Transfusion; 1994 Jun; 34(6):517-20. PubMed ID: 8023393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Iron Chelating Agents in Transfusion Dependent Thalassaemia Major Patients.
    Santra S; Bhattacharya A; Mukhopadhyay T; Agrawal D; Kumar S; Das P; Chakrabarty P
    Mymensingh Med J; 2015 Oct; 24(4):838-44. PubMed ID: 26620028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neocytopheresis: a new approach for the transfusion of patients with thalassaemia major.
    Triadou P; Girot R; Rebibo D; Lemau D; Mattlinger B; Bolo P; Maier-Redelsperger M; Barritault L
    Eur J Pediatr; 1986 Apr; 145(1-2):10-3. PubMed ID: 3732311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinically significant red blood cell antibodies in chronically transfused patients: a survey of Chinese thalassemia major patients and literature review.
    Cheng CK; Lee CK; Lin CK
    Transfusion; 2012 Oct; 52(10):2220-4. PubMed ID: 22339270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How I manage red cell transfusions in patients with sickle cell disease.
    Rees DC; Robinson S; Howard J
    Br J Haematol; 2018 Feb; 180(4):607-617. PubMed ID: 29377071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic stem cell transplantation for people with ß-thalassaemia major.
    Jagannath VA; Fedorowicz Z; Al Hajeri A; Hu N; Sharma A
    Cochrane Database Syst Rev; 2011 Oct; (10):CD008708. PubMed ID: 21975785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients.
    Lo SC; Chang JS; Lin SW; Lin DT
    Transfusion; 2005 May; 45(5):761-5. PubMed ID: 15847666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent Egyptian thalassemic patients.
    Saied DA; Kaddah AM; Badr Eldin RM; Mohaseb SS
    J Pediatr Hematol Oncol; 2011 Aug; 33(6):409-14. PubMed ID: 21792035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A home blood transfusion programme for beta-thalassaemia patients.
    Madgwick KV; Yardumian A
    Transfus Med; 1999 Jun; 9(2):135-8. PubMed ID: 10354383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sickle cell anemia and transfusion safety in Bamako, Mali. Seroprevalence of HIV, HBV and HCV infections and alloimmunization belonged to Rh and Kell systems in sickle cell anemia patients].
    Diarra AB; Guindo A; Kouriba B; Dorie A; Diabaté DT; Diawara SI; Fané B; Touré BA; Traoré A; Gulbis B; Diallo DA
    Transfus Clin Biol; 2013 Dec; 20(5-6):476-81. PubMed ID: 23916574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal blood grouping and antibody screening for safe transfusion.
    Makarovska-Bojadzieva T; Blagoevska M; Kolevski P; Kostovska S
    Prilozi; 2009 Jul; 30(1):119-28. PubMed ID: 19736535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program.
    el-Danasoury AS; Eissa DG; Abdo RM; Elalfy MS
    Transfusion; 2012 Jan; 52(1):43-7. PubMed ID: 21745214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfusion support for haemoglobinopathies.
    Greenwalt TJ; Zelenski KR
    Clin Haematol; 1984 Feb; 13(1):151-65. PubMed ID: 6373080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major.
    Richardson ME; Matthews RN; Alison JF; Menahem S; Mitvalsky J; Byrt E; Harper RW
    Aust N Z J Med; 1993 Dec; 23(6):656-61. PubMed ID: 8141693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
    Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.